Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kirsten, O. Holz, R. Tal-Singer, H. Magnussen, H. Watz (Grosshandorf, Hanover, Germany; King of Prussia, United States Of America). The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers. Eur Respir J 2012; 40: Suppl. 56, 2170

Member's Comments

No comment yet.

Related content which might interest you: The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005 Ceramide-1-phosphate decreases allergic airway inflammation, remodeling and hyperresponsiveness by inhibition of phosphorilation of NF-kappa B, Akt, MAPK p-38 in dendritic cells Source: Annual Congress 2010 - Models of airways disease Year: 2010 Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Exposure to LPS induces the upregulation of p38 MAPK in human bronchial epithelium in vivo Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007 p38 MAP kinase mediates apoptosis related to ventilator associated lung injury Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells Source: Eur Respir J 2003; 22: 43-49 Year: 2003 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 P38 MAPK and MMP-9 mediate airway mucus hypersecretion induced by acrolein Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling Source: Eur Respir J 2005; 26: Suppl. 49, 713s Year: 2005 Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017